SEC Form 4 · accession 0000899243-19-002190
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mehrdad Mobasher
Officer — Chief Medical Officer
Period of report
Jan 28, 2019
Accepted (ET)
Jan 30, 2019 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.88 | Jan 28, 2019 | A | 210,000 | A | — | Jan 28, 2029 | Common Stock | 210,000 | 210,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to twenty-five percent (25%) of the shares subject to the option on January 28, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.